Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience.
Ann Hematol
; 101(12): 2777-2779, 2022 12.
Article
in En
| MEDLINE
| ID: mdl-36104630
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms, Plasma Cell
/
Multiple Myeloma
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Ann Hematol
Journal subject:
HEMATOLOGIA
Year:
2022
Type:
Article
Affiliation country:
Italy